Controlling adenoviral replication to induce oncolytic efficacy

Open Gene Therapy Journal

Volumn 3, Issue , 2010, Pages 15-23

  Fillat, Cristina ^a,b   José, Anabel ^a,b   Bofill de Ros, Xavier ^a,b   Mato Berciano, Ana ^a,b   Maliandi, Maria Victoria ^a,b   Abate Daga, Daniel ^a,b,c  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Cancer gene therapy; Cancer virotherapy; Insulators; Oncolysis; Post transcriptional targeting; Transcriptional targeting; Tumor microenvironment

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; E1A PROTEIN; E1B PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MESOTHELIN; MICRORNA; ONCOLYTIC ADENOVIRUS; ONYX 015; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE R; RETINOBLASTOMA PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR CTCF; TRANSCRIPTION FACTOR E2F; UROKINASE RECEPTOR; UROPLAKIN; WNT PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADENOVIRUS; ARTICLE; BREAST CANCER; CELL DIVISION; CYTOTOXICITY; FEEDBACK SYSTEM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HEAD AND NECK CANCER; HUMAN; INSULATOR ELEMENT; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROCESSING; RNA PROCESSING; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIROLOGY; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 77953765248     PISSN: None     EISSN: 18750370     Source Type: Journal    
DOI: 10.2174/1875037001003020015     Document Type: Article

References (114)

1. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptionalcontrol in cancer gene therapy and viral oncolysis. Adv Drug DelivRev 2009; 61(7-8): 554-71.
2. Kim E, Kim JH, Shin HY, et al. Ad-mTERT delta19, a conditionalreplication competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in acancer cell specific manner. Hum Gene Ther 2003; 14(15): 1415-28.
3. Zhang Q, Nie M, Sham J, et al. Effective gene viral therapy fortelomerase positive cancers by selective replicative competentadenovirus combining with endostatin gene. Cancer Res 2004;64(15): 5390-7.
4. Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene2004; 23(2): 457-64.
5. Lei N, Shen FB, Chang JH, et al. An oncolytic adenovirus expressing granulocyte macrophage colony stimulating factor shows improved specificity and efficacy for treating human solid tumors.Cancer Gene Ther 2009; 16(1): 33-43.
6. Dong F, Wang L, Davis JJ, et al. Eliminating established tumor innu/nu nude mice by a tumor necrosis factor alpha related apopto-sis inducing ligandarmed oncolytic adenovirus. Clin Cancer Res2006; 12(17): 5224-30.
7. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by atropism modified telomerase specific replication selective adenovi-ral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005; 24(19):3130-40.
8. Kuppuswamy M, Spencer JF, Doronin K, et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors dueto hTERT promoterregulated E4 gene expression. Gene Ther2005; 12(22): 1608-17.
9. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancervirotherapy. Cancer Gene Ther 2009; 16(6): 473-88.
10. Bilsland AE, Merron A, Vassaux G, Keith WN. Modulation oftelomerase promoter tumor selectivity in the context of oncolyticadenoviruses. Cancer Res 2007; 67(3): 1299-307.
11. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, AminKM. An E2F-responsive replication selective adenovirus targetedto the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002; 62(12): 3438-47.
12. Ryan PC, Jakubczak JL, Stewart DA, et al. Antitumor efficacy andtumor selective replication with a single intravenous injection ofOAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004; 11(8): 555-69.
13. Li Y, Idamakanti N, Arroyo T, et al. Dual promoter controlledoncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res2005; 11(24 1): 8845-55.
14. Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med 2007; 9(9): 764-78.
15. Alonso MM, Cascallo M, Gomez-Manzano C, et al. ICOVIR-5shows E2F1 addiction and potent antiglioma effect in vivo. CancerRes 2007; 67(17): 8255-63.
16. Cascallo M, Alonso MM, Rojas JJ, et al. Systemic toxicity efficacyprofile of ICOVIR-5, a potent and selective oncolytic adenovirusbased on the pRB pathway. Mol Ther 2007;15(9): 1607-15.
17. Rojas JJ, Cascallo M, Guedan S, et al. A modified E2F-1 promoterimproves the efficacy to toxicity ratio of oncolytic adenoviruses.Gene Ther 2009; 16(12): 1441-51.
18. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced,cyclooxygenase-2 promoter based conditionally replicative adeno-virus for pancreatic cancer. Gastroenterology 2003; 125(4): 1203-18.
19. Davydova J, Le LP, Gavrikova T, et al. Infectivity-enhanced cy-clooxygenase-2-based conditionally replicative adenoviruses foresophageal adenocarcinoma treatment. Cancer Res 2004; 64(12):4319-27.
20. Shirakawa T, Hamada K, Zhang Z, et al. A cox-2 promoter-basedreplication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res2004;10(13): 4342-8.
21. Ono HA, Davydova JG, Adachi Y, et al. Promoter-controlledinfectivity-enhanced conditionally replicative adenoviral vectorsfor the treatment of gastric cancer. J Gastroenterol 2005; 40(1): 31-42.
22. Tekant Y, Davydova J, Ramirez PJ, et al. Oncolytic adenoviraltherapy in gallbladder carcinoma. Surgery 2005; 137(5): 527-35.
23. Hoffmann D, Wildner O. Restriction of adenoviral replicationto the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Mol Cancer Ther 2006;5(2): 374-81.
24. Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evalua-tion of survivin, midkine and CXCR4 promoters for transcriptionaltargeting of glioma gene therapy. Cancer Biol Ther 2007; 6(5):679-85.
25. Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven andfiber modified oncolytic adenovirus exhibits potent antitumor ac-tivity in established intracranial glioma. Hum Gene Ther 2007;18(7): 589-602.
26. Nandi S, Ulasov IV, Tyler MA, et al. Low-dose radiation enhancessurvivin-mediated virotherapy against malignant glioma stem cells.Cancer Res 2008; 68(14): 5778-84.
27. Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cellstarget intracranial glioma to deliver an oncolytic adenovirus in vivo.Gene Ther 2009; 16(2): 262-78.
28. Ulasov IV, Sonabend AM, Nandi S, et al. Combination of adenovi-ral virotherapy and temozolomide chemotherapy eradicatesmalignant glioma through autophagic and apoptotic cell death invivo. Br J Cancer 2009; 100(7): 1154-64.
29. Zhu ZB, Chen Y, Makhija SK, et al. Survivin promoter-basedconditionally replicative adenoviruses target cholangiocarcinoma.Int J Oncol 2006; 29(5): 1319-29.
30. Li B, Liu X, Fan J, et al. A survivin-mediated oncolytic adenovirusinduces non-apoptotic cell death in lung cancer cells and showsantitumoral potential in vivo. J Gene Med 2006; 8(10): 1232-42.
31. Zhu ZB, Rivera AA, Makhija SK, et al. Targeting lung cancerusing an infectivity enhanced CXCR4-CRAd. Lung Cancer 2007;55(2): 145-56.
32. Stoff-Khalili MA, Rivera AA, Stoff A, et al. Combining high selec-tivity of replication via CXCR4 promoter with fiber chimerism foreffective adenoviral oncolysis in breast cancer. Int J Cancer 2007;120(4): 935-41.
33. Zhu ZB, Mathis JM, Makhija SK, et al. Targeting of a condition-ally replicative adenovirus agent to human squamous cell carcino-mas of the head and neck. Int J Oncol 2007; 31(5): 1213-22.
34. Huch M, Gros A, Jose A, et al. Urokinase-type plasminogen activa-tor receptor transcriptionally controlled adenoviruses eradicatepancreatic tumors and liver metastasis in mouse models. Neoplasia2009; 11(6): 518-28, 4 p following 28.
35. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus)improves the efficacy of replicating adenoviruses that target coloncancer. Cancer Res 2005; 65(15): 6882-90.
36. Peerlinck I, Merron A, Baril P, et al. Targeted radionuclide therapyusing a Wnt-targeted replicating adenovirus encoding the Na/Isymporter. Clin Cancer Res 2009; 15(21): 6595-601.
37. Zhang L, Akbulut H, Tang Y, et al. Adenoviral vectors with E1Aregulated by tumor-specific promoters are selectively cytolytic forbreast cancer and melanoma. Mol Ther 2002; 6(3): 386-93.
38. Banerjee NS, Rivera AA, Wang M, et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypiccultures. Mol Cancer Ther 2004; 3(4): 437-49.
39. Sagawa T, Yamada Y, Takahashi M, et al. Treatment of hepatocel-lular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology 2008; 48(3): 828-40.
40. Hsieh JL, Lee CH, Teo ML, et al. Transthyretin-driven oncolyticadenovirus suppresses tumor growth in orthotopic and ascitesmodels of hepatocellular carcinoma. Cancer Sci 2009; 100(3): 537-45.
41. Li Y, Chen Y, Dilley J, et al. Carcinoembryonic antigen-producingcell-specific oncolytic adenovirus, OV798, for colorectal cancertherapy. Mol Cancer Ther 2003; 2(10): 1003-9.
42. Cafferata EG, Maccio DR, Lopez MV, et al. A novel A33 pro-moter-based conditionally replicative adenovirus suppresses tumorgrowth and eradicates hepatic metastases in human colon cancermodels. Clin Cancer Res 2009; 15(9): 3037-49.
43. Zhang J, Ramesh N, Chen Y, et al. Identification of humanuroplakin II promoter and its use in the construction of CG8840, aurothelium-specific adenovirus variant that eliminates establishedbladder tumors in combination with docetaxel. Cancer Res 2002;62(13): 3743-50.
44. Horst M, Brouwer E, Verwijnen S, et al. Targeting malignantgliomas with a glial fibrillary acidic protein (GFAP)-selective on-colytic adenovirus. J Gene Med 2007; 9(12): 1071-9.
45. Tsuruta Y, Pereboeva L, Breidenbach M, et al. A fiber-modifiedmesothelin promoter-based conditionally replicating adenovirus fortreatment of ovarian cancer. Clin Cancer Res 2008; 14(11): 3582-8.
46. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706,a replication-competent, PSA selective oncolytic adenovirus, forthe treatment of locally recurrent prostate cancer following radia-tion therapy. Cancer Res 2001; 61(20): 7464-72.
47. Ahmed A, Thompson J, Emiliusen L, et al. A conditionally repli-cating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat Biotechnol 2003; 21(7):771-7.
48. Särkioja M, Hakkarainen T, Eriksson M, et al. Thecyclo-oxygenase 2 promoter is induced in nontarget cells followingadenovirus infection, but an AU-rich 3prime-untranslated regiondestabilization element can increase specificity. Gene Med 2008;10(7): 744-53.
49. Stoff-Khalili M, Rivera A, Nedeljkovic-Kurepa A, et al. Cancer-specific targeting of a conditionally replicative adenovirus usingmRNA translational control. Breast Cancer Res Treatment 2008;108(1): 43-55.
50. Brown BD, Venneri MA, Zingale A, Sergi LS, Naldini L. Endoge-nous microRNA regulation suppresses transgene expression inhematopoietic lineages and enables stable gene transfer. Nat Med2006; 12(5): 585-91.
51. Edge RE, Falls TJ, Brown CW, et al. A let-7 MicroRNA-sensitivevesicular stomatitis virus demonstrates tumor-specific replication.Mol Ther 2008; 16(8): 1437-43.
52. Kelly EJ, Hadac EM, Greiner S, Russell SJ. EngineeringmicroRNA responsiveness to decrease virus pathogenicity. NatMed 2008; 14(11): 1278-83.
53. Lee CYF, Rennie PS, Jia WWG. MicroRNA Regulation of Onco-lytic Herpes Simplex Virus-1 for Selective Killing of Prostate Can-cer Cells. Clin Cancer Res 2009; 15(16): 5126-35.
54. Ylosmaki E, Hakkarainen T, Hemminki A, et al. Generation of aconditionally replicating adenovirus based on targeted destructionof E1A mRNA by a cell type-specific MicroRNA. J Virol 2008;82(22): 11009-15.
55. Cawood R, Chen HH, Carroll F, et al. Use of tissue-specificmicrorna to control pathology of wild-type adenovirus withoutattenuation of its ability to kill cancer cells. PLoS Pathog 2009;5(5): e1000440.
56. Barker DD, Berk AJ. Adenovirus proteins from both E1B readingframes are required for transformation of rodent cells by viral in-fection and DNA transfection. Virology 1987; 156(1): 107-21.
57. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutantthat replicates selectively in p53-deficient human tumor cells. Sci-ence 1996; 274(5286): 373-6.
58. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export,rather than p53 inactivation, determines ONYX-015 tumor selectiv-ity. Cancer Cell 2004; 6(6): 611-23.
59. Bandara LR, La Thangue NB. Adenovirus E1a prevents the retino-blastoma gene product from complexing with a cellular transcrip-tion factor. Nature 1991; 351(6326): 494-7.
60. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolyticadenovirus targeting the Rb pathway produces anti-glioma effect invivo. Oncogene 2000; 19(1): 2-12.
61. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicativeadenovirus with enhanced infectivity shows improved oncolyticpotency. Clin Cancer Res 2001; 7(1): 120-6.
62. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovariancancer with a tropism modified oncolytic adenovirus. Cancer Res2002; 62(5): 1266-70.
63. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutantthat demonstrates potent and selective systemic anti-tumoral effi-cacy. Nat Med 2000; 6(10): 1134-9.
64. Howe JA, Mymryk JS, Egan C, Branton PE, Bayley ST.Retinoblastoma growth suppressor and a 300-kDa protein appear toregulate cellular DNA synthesis. Proc Natl Acad Sci USA 1990;87(15): 5883-7.
65. Kitajewski J, Schneider RJ, Safer B, et al. Adenovirus VAI RNAantagonizes the antiviral action of interferon by preventing activa-tion of the interferon-induced eIF-2 alpha kinase. Cell 1986; 45(2):195-200.
66. Mundschau LJ, Faller DV. Oncogenic ras induces an inhibitorof double-stranded RNA-dependent eukaryotic initiation factor 2alpha-kinase activation. J Biol Chem 1992; 267(32): 23092-8.
67. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent onco-lysis with an adenovirus VAI mutant. Cancer Res 2003; 63(17):5544-50.
68. Cascallo M, Gros A, Bayo N, et al. Deletion of VAI and VAIIRNA genes in the design of oncolytic adenoviruses. Hum GeneTher 2006; 17(9): 929-40.
69. Macaluso M, Russo G, Cinti C, et al. Ras family genes: an interest-ing link between cell cycle and cancer. J Cell Physiol 2002; 192(2):125-30.
70. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. Theorganizing principle: microenvironmental influences in the normaland malignant breast. Differentiation 2002; 70(9-10): 537-46.
71. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1): 57-70.
72. Weinberg R. The biology of cancer. Garland Science. New York Taylor & Francis Group, LLC 2007.
73. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solidtumour. Nat Rev Cancer 2008; 8(9): 705-13.
74. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancerand approaches to enforce tumour regression. Nature 2006;441(7092): 437-43.
75. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks ofhuman cancer. J Cell Biochem 2009; 107(6): 1053-62.
76. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New onco-lytic adenoviruses with hypoxia- and estrogen receptor-regulatedreplication. Hum Gene Ther 2002; 13(14): 1737-50.
77. Cuevas Y, Hernandez-Alcoceba R, Aragones J, et al. Specificoncolytic effect of a new hypoxia-inducible factor-dependentreplicative adenovirus on von Hippel-Lindau-defective renal cellcarcinomas. Cancer Res 2003; 63(20): 6877-84.
78. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF)activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22(14): 2065-72.
79. Cho WK, Seong YR, Lee YH, et al. Oncolytic effects of adenovi-rus mutant capable of replicating in hypoxic and normoxic regionsof solid tumor. Mol Ther 2004; 10(5): 938-49.
80. Irving J, Wang Z, Powell S, et al. Conditionally replicativeadenovirus driven by the human telomerase promoter providesbroad-spectrum antitumor activity without liver toxicity. CancerGene Ther 2004; 11(3): 174-85.
81. Lam JT, Kanerva A, Bauerschmitz GJ, et al. Inter-patient variationin efficacy of five oncolytic adenovirus candidates for ovariancancer therapy. J Gene Med 2004; 6(12): 1333-42.
82. Takayama K, Reynolds PN, Adachi Y, et al. Vascular endothelialgrowth factor promoter-based conditionally replicative adenovi-ruses for pan-carcinoma application. Cancer Gene Ther 2007;14(1): 105-16.
83. Wang X, Su C, Cao H, et al. A novel triple-regulated oncolyticadenovirus carrying p53 gene exerts potent antitumor efficacy oncommon human solid cancers. Mol Cancer Ther 2008; 7(6): 1598-603.
84. Bortolanza S, Bunuales M, Otano I, et al. Treatment of PancreaticCancer With an Oncolytic Adenovirus Expressing Interleukin-12 inSyrian Hamsters. Mol Ther 2009; 17(4): 614-22.
85. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptionaltargeting of conditionally replicating adenovirus to dividing endo-thelial cells. Gene Ther 2002; 9(14): 972-9.
86. Hemminki A, Kanerva A, Kremer EJ, et al. A canine conditionallyreplicating adenovirus for evaluating oncolytic virotherapy in asyngeneic animal model. Mol Ther 2003; 7(2): 163-73.
87. Lopez M, Viale D, Cafferata E, et al. Tumor associated stromalcells play a critical role on the outcome of the oncolytic efficacy ofconditionally replicative adenoviruses. PLoS One 2009; 4(4):e5119.
88. Kanerva A, Lavilla-Alonso S, Raki M, et al. Systemic therapy forcervical cancer with potentially regulatable oncolytic adenoviruses.PLoS One 2008; 3(8): e2917.
89. Jin F, Xie Z, Kuo CJ, Chung LW, Hsieh CL. Cotargeting tumorand tumor endothelium effectively inhibits the growth of humanprostate cancer in adenovirus-mediated antiangiogenesis andoncolysis combination therapy. Cancer Gene Ther 2005; 12(3):257-67.
90. Hatfield L, Hearing P. Redundant elements in the adenovirus type 5inverted terminal repeat promote bidirectional transcription in vitroand are important for virus growth in vivo. Virology 1991; 184(1):265-76.
91. Leza MA, Hearing P. Cellular Transcription Factor Binds toAdenovirus Early Region Promoters and to a Cyclic AMPResponse Element. J Virol 1988; 3003-13.
92. Ring C, Harris J, Hurst H, Lemoine N. Suicide gene expressioninduced in tumour cells transduced with recombinant adenoviral,retroviral and plasmid vectors containing the ERBB2 promoter.Gene Ther 1996; 3(12): 1094-103.
93. Shi Q, Wang Y, Worton R. Modulation of the specificity and activ-ity of a cellular promoter in an adenoviral vector. Hum Gene Ther1997; 8(4): 403-10.
94. Steinwaerder D, Lieber A. Insulation from viral transcriptionalregulatory elements improves inducible transgene expression fromadenovirus vectors in vitro and in vivo. Gene Ther 2000; 7: 556-67.
95. Hoffmann D, Jogler C, Wildner O. Effects of the Ad5 upstream E1region and gene products on heterologous promoters. J Gene Med2005; 7(10): 1356-66.
96. Wallace JA, Felsenfeld G. We gather together: insulators andgenome organization. Curr Opin Genet Dev 2007; 15(5): 400-7.
97. Burgess-Beusse B, Farrell C, Gaszner M, et al. The insulation ofgenes from external enhancers and silencing chromatin. Proc NatlAcad Sci USA 2002; 99(4): 16433-7.
98. Razin S, Farrell C, Recillas-Targa F. Genomic domains and regula-tory elements operating at the domain level. Int Rev Cytol 2003;226: 63-125.
99. Chung J, Whiteley M, Felsenfeld G. A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells andprotects against position effect in Drosophila. Cell 1993; 74(3): 505-14.
100. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, et al. Position-effectprotection and enhancer blocking by the chicken -globin insulator areseparable activities. Proc Natl Acad Sci USA 2002; 99: 6883-8.
101. West A, Gaszner M, Felsenfeld G. Insulators: many functions,many mechanisms. Genes Dev 2002; 16(3): 271-88.
102. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional andepigenetic mechanisms. Nat Rev Genet 2006; 7(9): 703-13.
103. Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquelyversatile transcription regulator linked to epigenetics and disease.Trends Genet 2001; 17(9): 520-7.
104. Williams A, Flavell R. The role of CTCF in regulating nuclearorganization. J Exp Med 2008; 205(4): 747-50.
105. Ye X, Liang M, Meng X, et al. Insulation from viral transcriptionalregulatory elements enables improvement to hepatoma-specificgene expression from adenovirus vectors. Biochem Biophys ResCommun 2003; 307: 759-64.
106. Martin-Duque P, Jezzard S, Kaftansis L, Vassaux G. Directcomparison of the insulating properties of two genetic elements inan adenoviral vector containing two different expression cassettes.Hum Gene Ther 2004; 15(10): 995-1002.
107. Rohmer S, Mainka A, Knippertz I, Hesse A, Nettelbeck DM.Insulated hsp70B! promoter: stringent heat-inducible activity inreplication-deficient, but not replication-competent adenoviruses. JGene Med 2008; 10: 340-54.
108. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicativeadenovirus with enhanced infectivity shows improved oncolyticpotency. Clin Cancer Res 2001; 7(1): 120-6.
109. Majem M, Cascallo M, Bayo-Puxan N, et al. Control of E1A underan E2F-1 promoter insulated with the myotonic dystrophy locusinsulator reduces the toxicity of oncolytic adenovirusAd-Delta24RGD. Cancer Gene Ther 2006; 13(7): 696-705.
110. Danielsson A, Dzojic H, Nilsson B, Essand M. Increased therapeu-tic efficacy of the prostate-specific oncolytic adenovirusAd lsqbI//PPT-E1A rsqb by reduction of the insulator size andintroduction of the full-length E3 region. Cancer Gene Ther 2008;15(4): 203-13.
111. Emery DW, Yannaki E, Tubbl J, et al. A chromatin insulatorprotects retrovirus vectors from chromosomal position effects. ProcNatl Acad Sci USA 2000; 97(16): 9150-5.
112. Ramezani A, Hawley T, Hawley R. Performance- and safety-enhanced lentiviral vectors containing the human interferon-betascaffold attachment region and the chicken beta-globin insulator.Blood 2003; 101(12): 4717-24.
113. Kelly E, Russell SJ. History of oncolytic viruses: genesis to geneticengineering. Mol Ther 2007; 15(4): 651-9.
114. Albini A, Sporn MB. The tumour microenvironment as a target forchemoprevention. Nat Rev Cancer 2007; 7(2): 139-47.